Real‐World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA Registry
Alimentary Pharmacology & Therapeutics · 2026-09 · 64 (6) · 781-791
DOI: 10.1111/apt.70783 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 10.06.2026. Verfasst von Manuel Barreiro-de Acosta und 59 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Complexo Hospitalario Universitario de Santiago and Fundación Instituto de Investigación Sanitaria de Santiago de Com…. Hauptthemen laut MEDLINE: Crohn Disease, Antibodies, Monoclonal. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background and Aims Risankizumab, a selective interleukin‐23 p19 inhibitor, has demonstrated efficacy in clinical trials for moderate‐to‐severe Crohn's disease, but real‐world data in highly refractory populations are limited. We evaluated the short‐term effectiveness and outcomes at last follow‐up of risankizumab and the impact of prior advanced therapy exposure.
Methods
This multicentre observational study included adult patients with predominantly refractory Crohn's disease treated with risankizumab and registered in the ENEIDA registry. Steroid‐free clinical remission, defined as a Harvey–Bradshaw Index ≤ 4 without systemic corticosteroids, was assessed at weeks 8–12 and at the last available follow‐up visit. Multivariable logistic regression was used to identify factors associated with remission at last follow‐up.
Results
A total of 857 patients with predominantly refractory Crohn's disease were included. Steroid‐free clinical remission was achieved in 56% of patients at weeks 8–12 and in 61% at last follow‐up (mean follow‐up: 7.4 months). Remission rates were higher in patients previously exposed to ≤ 2 biologic therapies than in those exposed to > 2 biologic therapies at both time points ( p < 0.001). Prior ustekinumab exposure was associated with lower remission rates in unadjusted analyses but was not independently associated with remission at last follow‐up. Treatment‐related adverse events occurred in 8% of patients, with no serious adverse events.
Conclusions
In this large real‐world cohort of patients with refractory Crohn's disease, risankizumab achieved clinically meaningful steroid‐free clinical remission, both at early assessment and at last follow‐up, with effectiveness primarily influenced by cumulative biologic exposure and demonstrating a favourable safety profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Complexo Hospitalario Universitario de Santiago and Fundación Instituto de Investigación Sanitaria de Santiago de Compostela (FIDIS), Santiago de Compostela, Spain.
- Department of Gastroenterology, Hospital Universitari MútuaTerrassa, Terrassa, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), Terrassa, Spain.
- Department of Gastroenterology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Biomédica Gregorio Marañón (IiSGM), Madrid, Spain.
- Department of Gastroenterology, Hospital Universitari i Politècnic La Fe, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
- Department of Gastroenterology, Hospital Universitario Río Hortega, Valladolid, Spain.
- Universidad de Sevilla. Facultad de Medicina. Department of Gastroenterology, Hospital Universitario Virgen Macarena, Sevilla, Spain.
ORCID-Profile: Manuel Barreiro-de Acosta, Lucía Zabalza, María Dolores Martín-Arranz, Javier P Gisbert, Elena Ricart, Mari Fe Garcia-Sepulcre, Alejandro Hernandez-Camba, Eduard Brunet-Mas, Francisco Mesonero
Zitieren
APA
Barreiro-de Acosta, M., Zabana, Y., Nieto-García, L., Poncela, M., Aguas, M., Martínez-Cuevas, C., Argüelles-Arias, F., Calvo, M., Gargallo-Puyuelo, C. J., Zabalza, L., Trastoy, P. V., Boscá-Watts, M. M., Ceballos, D., Pascual, C. M., Rodríguez-Moranta, F., de Castro Parga, M. L., Suárez, P., Camps, B., Royo, V., …, & Menacho, M. (2026). Real‐World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA Registry. Alimentary Pharmacology & Therapeutics, 64(6), 781-791. https://doi.org/10.1111/apt.70783
Vancouver
Barreiro-de Acosta M, Zabana Y, Nieto-García L, Poncela M, Aguas M, Martínez-Cuevas C, et al. Real‐World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA Registry. Alimentary Pharmacology & Therapeutics. 2026;64(6):781-791. doi:10.1111/apt.70783
BibTeX
@article{BarreirodeAcosta2026,
author = {Barreiro-de Acosta, Manuel and Zabana, Yamile and Nieto-García, Laura and Poncela, Marta and Aguas, Mariam and Martínez-Cuevas, Cristina and Argüelles-Arias, Federico and Calvo, Marta and Gargallo-Puyuelo, Carla J and Zabalza, Lucía and Trastoy, Pilar Varela and Boscá-Watts, Maia M and Ceballos, Daniel and Pascual, Cristina Martínez and Rodríguez-Moranta, Francisco and de Castro Parga, María Luisa and Suárez, Patricia and Camps, Blau and Royo, Vanesa and Baston-Rey, Iria and de Francisco, Ruth and García-Lopez, Santiago and Martín-Arranz, María Dolores and Bermejo, Fernando and Alonso-Abreu, Inmaculada and Gisbert, Javier P and Rivero, Montserrat and Sicilia, Beatriz and Nicolás, Isabel and Teller, Marta and Díaz, Ángel Ponferrada and Ricart, Elena and Algara, María and Fradejas, Paola and Robledo, Pilar and Madero, Lucía and Elorza, Ainara and Piqueras, Marta and Garcia-Sepulcre, Mari Fe and Sesé, Eva and Hernandez-Camba, Alejandro and Izquierdo, Sandra and Trapero, Ana M and Iglesias, Eva and Diz-Lois Palomares, María Teresa and Brunet-Mas, Eduard and Castro Poceiro, Jesús and Busquets, David and Manosa, Miriam and Pajares, Ramón and Ferrer, Juan A and Carpio, Daniel and Mesonero, Francisco and Bujanda, Luis and Lorente, Rufo and Santos, Javier and Flores, Carlos Martínez and González-Muñoza, Carlos and Martín, Daniel and Menacho, Margarita},
title = {Real‐World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA Registry},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
volume = {64},
number = {6},
pages = {781--791},
doi = {10.1111/apt.70783}
}
EUVIMED